Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls

Heidrich, B.; Vital, Marius; Plumeier, Iris; Döscher, Nico; Kahl, Silke; Kirschner, J.; Ziegert, S.; Solbach, Philipp; Lenzen, Henrike; Potthoff, Andrej; Manns, Michael P.; Wedemeyer, Heiner; Pieper, Dietmar H.

doi:10.1111/liv.13485

Cited by 80 publications

(102 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, current medications (lactulose, rifaximin, fiber supplements, proton pump inhibitors [PPIs], nonselective beta‐blockers [NSBBs], or antiviral therapy for hepatitis B) as well as lifestyle issues (smoking and alcohol history) were obtained at the same time . Comorbid conditions, such as diabetes and metabolic syndrome (MetS) and history of sustained virological response (SVR) to hepatitis C therapy, were also assessed …”

Section: Methodsmentioning

confidence: 99%

“…(12) Comorbid conditions, such as diabetes and metabolic syndrome (MetS) and history of sustained virological response (SVR) to hepatitis C therapy, were also assessed. (13,14) Patients with cirrhosis were prospectively followed for at least 90 days for nonelective hospitalizations that were determined according to the supervising clinicians at each site. The 90-day interval was chosen because of the validity of the MELD score for that duration and also the high likelihood of readmissions during that interval in past cohorts.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Diet affects gut microbiota and modulates hospitalization risk differentially in an international cirrhosis cohort

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Diet affects gut microbiota and modulates hospitalization risk differentially in an international cirrhosis cohort

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Studies of HCV-associated liver disease on the microbiota are not very clear with results suggesting that the microbiota changes before cirrhosis and after cirrhosis. [31][32][33] Microbiota composition is variably affected by the eradication of the virus. 34 There is an increasing body of literature on HBV before the development of cirrhosis.…”

Section: Composition and Functional Changes In Microbiota In Patientsmentioning

confidence: 99%

Microbiota changes and intestinal microbiota transplantation in liver diseases and cirrhosis

Bajaj

Khoruts

2020

Journal of Hepatology

131

View full text Add to dashboard Cite

Patients with chronic liver disease and cirrhosis demonstrate a global mucosal immune impairment, which is associated with altered gut microbiota composition and functionality. These changes progress along with the advancing degree of cirrhosis and can be linked with hepatic encephalopathy, infections and even prognostication independent of clinical biomarkers. Along with compositional changes, functional alterations to the microbiota, related to short-chain fatty acids, bioenergetics and bile acid metabolism, are also associated with cirrhosis progression and outcomes. Altering the functional and structural profile of the microbiota is partly achieved by medications used in patients with cirrhosis such as rifaximin, lactulose, proton pump inhibitors and other antibiotics. However, the role of faecal or intestinal microbiota transplantation is increasingly being recognised. Herein, we review the challenges, opportunities and road ahead for the appropriate and safe use of intestinal microbiota transplantation in liver disease.

show abstract

“…They are essential for maintaining human health, as shown by their involvement in many important physiological processes, including nutrient metabolism, regulation of the immune system and pathogenic microorganism resistance. In the last five years, mounting evidence has underlined the significance of the associated structural changes in gut microbiota in the progression of infectious diseases . On the one hand, gut microbiota alters during the course of many different infectious diseases, such as the human immunodeficiency virus infection, tuberculosis and chronic hepatitis C .…”

Section: Introductionmentioning

confidence: 99%

The gut microbiota of hand, foot and mouth disease patients demonstrates down‐regulated butyrate‐producing bacteria and up‐regulated inflammation‐inducing bacteria

Zhu

et al. 2018

Acta Paediatrica

View full text Add to dashboard Cite

Aim: This study explored the gut microbiota of children with hand, foot and mouth disease (HFMD).Methods: We enrolled 15 cases with HFMD admitted to the West China Second Hospital, Sichuan University, China, from July to September 2016 at a median age of three years. The controls were 15 healthy children of a similar age who underwent routine health examinations at the hospital during the same period. Gut microbiota was analysed using high throughput 16S ribosomal deoxyribonucleic acid sequencing.Results: The gut microbiota in the HFMD patients was distinct from the controls. Compared with the controls, the composition of gut microbiota in the HFMD cases represented a reduction of two butyrate-producing bacteria, Ruminococcus (0.73 AE 1.28 versus 7.78 AE 20.01, p = 0.026) and Roseburia (0.67 AE 1.69 versus 1.61 AE 3.27, p = 0.024) and an up-regulation of Escherichia (5.26 AE 10.50 versus 1.59 AE 5.90,p < 0.01) and Enterococcus (4.12 AE 12.49 versus 0.12 AE 0.41, p = 0.015). Conclusion:The dysbiosis of gut microbiota of the HFMD cases included a reduction of butyrate-producing bacteria and an up-regulation of inflammation-inducing bacteria. These may have impaired the intestinal biological mucosal barrier and host immune functions, promoting the invasion of the enterovirus.

show abstract

Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls

Cited by 80 publications

References 36 publications

Diet affects gut microbiota and modulates hospitalization risk differentially in an international cirrhosis cohort

Diet affects gut microbiota and modulates hospitalization risk differentially in an international cirrhosis cohort

Microbiota changes and intestinal microbiota transplantation in liver diseases and cirrhosis

The gut microbiota of hand, foot and mouth disease patients demonstrates down‐regulated butyrate‐producing bacteria and up‐regulated inflammation‐inducing bacteria

Contact Info

Product

Resources

About